Introduction: A Healthcare Trend That Is Changing Grocery Carts
The GLP-1 impact on retail is becoming increasingly difficult for the food and beverage industry to ignore. As millions of consumers change how much and what they eat, the effects are beginning to ripple across supermarkets, restaurants, and packaged food companies.
For decades, the food and beverage (F&B) industry has adapted to changing consumer preferences, from low-fat diets and plant-based foods to organic and functional nutrition. Today, another trend is emerging that could reshape the industry’s future, which is GLP-1 weight-loss drugs.
GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound were first developed to treat Type 2 diabetes but are now widely used for weight management. These drugs help users feel full for longer, reduce food cravings, and naturally lower calorie intake. As millions of consumers change how much and what they eat, the effects are beginning to ripple across supermarkets, restaurants, and packaged food companies.
What once seemed like a healthcare innovation has evolved into a significant business consideration for food manufacturers. Instead of asking whether GLP-1 drugs will affect the F&B sector, companies are now focused on how quickly they should adapt to changing consumer eating habits and purchasing patterns.
The GLP-1 Boom: Why Everyone Is Talking About It
The adoption of GLP-1 medications has accelerated rapidly over the past two years. According to PwC, 21% of U.S. households now include a current GLP-1 user, up from just 9% in early 2025, highlighting how quickly these medications are entering mainstream use.
Unlike traditional diets, GLP-1 drugs work by slowing digestion and increasing satiety, allowing users to feel full with significantly less food. Many clinical studies have shown average weight loss of 15–20% of body weight, making these medicines one of the most effective obesity treatments available.
Their popularity is being supported by:
- Increasing physician prescriptions
- Expanding insurance coverage in some markets
- Growing awareness of obesity-related health risks
- Continued innovation, including oral GLP-1 therapies under development and launch
As adoption continues to grow, companies across the consumer goods industry are paying close attention and not because people are stopping eating, but because they are eating differently.
Consumers Are Buying Less, but Choosing Better
One of the biggest effects of GLP-1 drugs is the shift in consumer purchasing behavior. Appetite suppression means consumers naturally reduce the number of meals, snacks, and beverages they consume throughout the day. However, the bigger change lies in what they choose to eat.
PwC’s 2026 research found that households using GLP-1 drugs spend 5.5% less on groceries overall, while spending shifts toward fresh produce, protein-rich foods, and nutritional supplements. The quick-service restaurant spending also falls by 8.7%, reflecting lower meal frequency and smaller order sizes.
The consumers are increasingly looking for foods that provide greater nutritional value because every meal matters more when total food intake declines.
The changing priorities include:
- Higher protein intake
- More fibre-rich foods
- Functional beverages
- Fresh fruits and vegetables
- Products with vitamins and probiotics
Instead of simply eating less, consumers are becoming more intentional about what they put into their shopping baskets.
Which Food Categories Face the Greatest Pressure?
The GLP-1 impact on retail extends beyond lower food consumption. It is changing what consumers put in their shopping baskets and which categories receive their spending.
Not every food category will experience the same impact. The products driven by impulse purchases or frequent snacking may face greater challenges than those associated with nutrition and wellness.
1. Snacks and Confectionery
Snack foods are among the most exposed categories. Chips, chocolates, cookies, candies, and other indulgent products rely heavily on between-meal consumption. Since GLP-1 users report fewer cravings, these products may experience slower demand growth.
The research suggests spending on snacks declines noticeably after several months of GLP-1 use, reflecting reduced impulse eating.
Manufacturers may increasingly focus on:
- Portion-controlled packs
- High-protein snacks
- Reduced-sugar recipes
- Better-for-you alternatives
2. Sugary Beverages
Soft drinks and other high-calorie beverages may also face pressure as consumers reduce unnecessary calorie intake.
Instead, demand is shifting toward:
- Protein shakes
- Functional beverages
- Electrolyte drinks
- Vitamin-enriched beverages
- Zero-sugar products
As health becomes a larger purchase driver, beverage companies are investing more heavily in products that offer functional benefits rather than empty calories.
3. Restaurants
Restaurants are unlikely to lose customers entirely, but they could see changes in ordering patterns.
According to PwC, spending at quick-service restaurants declines among GLP-1 households, with categories such as pizza, chicken, burgers, and bakery products showing weaker demand. Many consumers also want smaller portions at proportionally lower prices.
This could encourage restaurants to introduce:
- Half-sized meals
- Protein-focused menu options
- Flexible portion sizes
- Healthier side dishes
The Biggest Winners Could Be Protein and Functional Nutrition
While some food categories face challenges, others are expected to benefit.
Consumers taking GLP-1 medications often prioritize foods that help maintain muscle mass while supporting weight loss. As a result, demand is increasing for:
- Greek yogurt
- Cottage cheese
- Protein bars
- Ready-to-drink protein shakes
- Lean meat products
- High-fibre cereals
- Functional nutrition products
The industry surveys also show that food manufacturers increasingly view protein as a long-term growth opportunity rather than a passing trend.
This creates opportunities for companies already operating in health-focused categories while encouraging traditional manufacturers to expand beyond indulgent products.
How Food & Beverage Companies Are Responding
The leading food companies are no longer treating GLP-1 drugs as a temporary trend. Instead, many are adapting their innovation strategies to meet changing consumer preferences.
Key responses include:
- Increasing protein content across product portfolios
- Reducing sugar and unhealthy fats
- Expanding functional nutrition offerings
- Introducing smaller pack sizes
- Reformulating existing products
- Highlighting nutritional benefits on packaging
The recent examples show the industry is already moving. Tata Consumer Products announced plans to launch foods and beverages designed to address nutritional gaps, such as protein, fibre, prebiotics, and probiotics, that may arise among GLP-1 users.
Meanwhile, Deloitte’s 2026 survey found that 89% of food and beverage companies are increasing investment in health and wellness products, while 30% are already adjusting product strategies in anticipation of demand changes linked to GLP-1 drugs.
The Industry Is Facing a Portfolio Shift, Not a Demand Collapse
Despite growing concerns, GLP-1 drugs are unlikely to eliminate demand for indulgent foods. Most consumers who use these medications still enjoy snacks, desserts, and restaurant meals, they simply consume them less frequently and in smaller quantities.
This means the biggest risk is not declining food demand but changing product mix.
Companies with diversified portfolios that include:
- Functional beverages
- Protein-rich products
- Healthy snacks
- Nutritional supplements
are likely to adapt more easily than businesses heavily dependent on confectionery or sugary beverages.
The industry research also projects that GLP-1 households could account for 35% of U.S. food and beverage unit sales by 2030, making this consumer segment too significant for manufacturers to ignore.
What Lies Ahead for the Food & Beverage Industry?
GLP-1 drugs represent one of the most significant shifts in consumer behaviour seen in recent years. While the industry has successfully adapted to previous trends such as low-fat diets, organic foods, and plant-based eating, GLP-1 adoption introduces a different challenge, it changes not only what consumers buy but how much they consume.
Rather than viewing GLP-1 drugs as a threat, food and beverage companies should see them as a catalyst for innovation. The future will likely belong to brands that deliver products combining great taste with high nutritional value, convenience, and functional benefits.
The era of “more food” may be giving way to the era of better food. Companies that respond by investing in protein-rich, nutrient-dense, and health-focused products will be better positioned to meet evolving consumer expectations. As GLP-1 adoption continues to rise, success in the food and beverage industry will depend not just on satisfying hunger, but on delivering greater value in every bite.
Interested in learning more about the packaged food and beverage sector? At CrispIdea, we publish in-depth equity research reports on leading global packaged food, beverage, snack, and consumer goods companies, covering their business models, financial performance, competitive positioning, product innovation, consumer trends, pricing strategies, growth drivers, and investment outlook. Visit our website to explore our latest research, industry insights, and company analyses.Â
Explore our latest research and insights.
Author
Aishwarya Dinesh operates at the intersection of Retail, E-commerce, and deep-tech innovation, leading research focused on disruptions shaping long-term value creation. A top-ranked global analyst known for high-conviction calls on companies like PepsiCo and Zalando, she evaluates how Generative AI, autonomous logistics, and tech-enabled supply chains influence intrinsic value and competitive moats across the consumer ecosystem. Her coverage spans leaders including Amazon, Walmart, Costco, Starbucks, Alibaba, and Lululemon, helping investors identify asymmetric opportunities and durable alpha.
FAQs
1. What are GLP-1 drugs, and why are they influencing the food and beverage industry?
GLP-1 drugs are medications primarily used to treat Type 2 diabetes and obesity by reducing appetite, slowing digestion, and helping users feel full for longer. As more consumers adopt these medications, they are eating smaller portions, snacking less, and choosing healthier foods. These changing consumption patterns are prompting food and beverage companies to adapt their product portfolios and innovation strategies.
2. Which food and beverage categories are most affected by GLP-1 adoption?
Categories such as confectionery, salty snacks, sugary beverages, and some fast-food offerings may face slower demand growth as consumers reduce calorie intake and impulse purchases. In contrast, high-protein foods, fresh produce, functional beverages, high-fibre products, and nutrient-dense meals are expected to benefit from shifting consumer preferences.
3. How are food and beverage companies responding to the GLP-1 trend?
Many food and beverage companies are reformulating products, increasing protein and fibre content, reducing sugar, and introducing healthier or portion-controlled options. Companies are also expanding their functional nutrition portfolios and investing in products that align with the growing demand for health and wellness, helping them adapt to evolving consumer eating habits.